Key insights
- Stifel raised its price target on Revolution Medicines (RVMD) to $215, citing a strong growth outlook and peak sales potential of $19.1 billion by 2035, primarily from its RAS(ON) inhibitors in pancreatic and lung cancer. The stock is near its 52-week high and considered overbought. Recent clinical data presentations at the American Association for Cancer Research meeting are driving positive sentiment. The analyst's increased target may lead to short-term positive momentum.
Investing.com - Stifel raised its price target on Revolution Medicines Inc. shares (NASDAQ:RVMD) to $215 from $170 while maintaining a Buy rating on the stock.
The firm values Revolution at approximately 3.7 times enterprise value to five-year forward sales for 2031, in line with its large-cap biotech peer group at around 3.4 times. Revolution currently has a market capitalization of $31.26 billion with nearly $4 billion in cash on its balance sheet following a financing of more than $2 billion last week. The stock is trading at $148.63, near its 52-week high of $155.70, following a remarkable 304% gain over the past year. According to an InvestingPro tip, the stock is currently trading in overbought territory based on RSI indicators.
Stifel models peak sales of approximately $19.1 billion by 2035, representing about $12.6 billion and $6.4 billion in blended RAS(ON) inhibitor credit across pancreatic ductal adenocarcinoma and non-small cell lung cancer, respectively.
The firm noted that the American Association for Cancer Research meeting is focused on daraxonrasib in pancreatic ductal adenocarcinoma following the RASolute 302 topline results last week and first-line pancreatic ductal adenocarcinoma conference abstracts.
Stifel also highlighted zoldonrasib data in second-line and later non-small cell lung cancer presented at the meeting. Despite the strong momentum, InvestingPro analysis suggests the stock may be overvalued relative to its Fair Value, with 16 additional ProTips available to help investors make informed decisions.
In other recent news, Revolution Medicines Inc. has reported updated Phase 1 clinical data for its lung cancer drug, zoldonrasib, at the American Association for Cancer Research Annual Meeting. The trial involved 40 patients with KRAS G12D non-small cell lung cancer, who received the drug at the recommended Phase 2 dose. Additionally, Revolution Medicines has successfully raised approximately $2.1 billion through concurrent public offerings of common stock and convertible senior notes. The company sold over 12 million shares at $142 per share and issued $500 million in convertible senior notes due 2033.
Analyst firms have also been active regarding Revolution Medicines. Mizuho reiterated an Outperform rating with a $140 price target following positive Phase III trial results for the cancer drug daraxonrasib. The RASolute 302 study met key survival endpoints in second-line pancreatic cancer. Meanwhile, H.C. Wainwright raised its price target for the company to $169, maintaining a Buy rating after positive topline results from the same trial. These developments reflect significant progress and interest in Revolution Medicines’ ongoing clinical trials and financial strategies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.